Sphere Bio

Sphere Bio is a pre-clinical stage biotechnology company focused on developing a novel class of immunotherapies using its proprietary Sphere platform. Originating from the Wyss Institute at Harvard University, the company's technology utilizes synthetic particles designed to mimic the function of antigen-presenting cells to trigger potent and specific T-cell responses. This approach aims to improve the efficacy of cancer vaccines and other mRNA-based therapies by enhancing delivery and immune activation. Sphere Bio is currently advancing its lead programs in oncology to address various solid tumor indications. The company's platform is designed to be modular, allowing for the rapid development of personalized treatments tailored to individual patient profiles.